Randomized Clinical Trials of Traditional Chinese Medicines for Treating Ulcerative Colitis: A Scoping Review

You-You Zheng, Xiao Wang, Jiang-Tao Si, Yu-Xin Sun, Wen-Bin Hou, Jian-Ping Liu, Yuan-Xi Li, Zhao-Lan Liu

Objective: Traditional Chinese medicines (TCMs) are efficacious against ulcerative colitis (UC). In recent years, the number of randomized clinical trials (RCTs) of TCM has increased. Thus, it is very important to summarize the basic characteristics, quality, and types of TCM interventions in published RCTs. This scoping review was performed to systematically identify and describe the current situations about RCTs of TCMs for treating UC. Hope to express the focus and specifics of nowadays research in TCM interventions in RCTs and evaluate their common disadvantages exposed to help advance in TCM researching. Materials and Methods: A scoping review was conducted according to the PRISMA extension for scoping reviews. We searched two English databases and four Chinese databases from the date of establishment of each database to January 2020. Data from RCTs focusing on any TCM treatment for patients with UC were extracted and evaluated. Selection and characterization were performed by two independent reviewers using predefined forms. All discrepancies were resolved by consensus discussion with a third reviewer. Microsoft Excel 2010 was used to extract the following data from the included studies: (1) basic information of the included studies including research ID, article title, publication language, journal, year of publication, and funding information; (2) patient information including gender, age, disease course, disease stage, severity, sample size; and (3) information on intervention measures, types of intervention measures, drug dosage forms, and treatment courses. Results: The search identified 2225 RCTs published between 1987 and 2020. These studies covered 36 provinces in China. The time frame of the RCTs was <28 days in approximately one-third of the RCTs (647, 29.08%). Only one RCT was published in English. Nearly three-quarters of RCTs (1665, 74.83%) did not report the severity of the disease. Three types of interventions were included in the RCTs: pharmacotherapy (2028, 91.15%), nonpharmacotherapy (57, 2.56%), and a combination of the two (140, 6.29%). The administration modes of the intervention groups were evaluated. Drug therapy involved 12 types of TCM dosage forms, which were decoctions, troches, powders, capsules, granules, pills, suppositories, ointments, injections, gels, oral liquids, and substitute tea according to the frequency of use. Nondrug intervention measures involved 10 treatment options, namely, acupuncture, moxibustion, hemospasia, auricular point, acupoint catgut embedding, acupoint injection, scraping, tuina, acupoint application, and five-tone therapy according to the frequency of use. Most studies included in this review were low in quality. This underscores the need for improvement in the quality of trial methodology in TCM RCTs.

Keywords: Dosage forms, randomized clinical trial, research status, scoping review, Traditional Chinese medicine, ulcerative colitis

INTRODUCTION

Ulcerative colitis (UC) is a chronic inflammatory disease affecting the colonic mucosa. Clinical manifestations include diarrhea, abdominal pain, bloody mucous stools, and systemic symptoms of different degrees, and the course of the disease is more than 4–6 weeks.[1] Current Western medicine options include treatment with 5-aminosalicylic acid preparations, glucocorticoids, immunosuppressants, biological agents, and surgical treatment.[2] Depending on the clinical severity, UC can be divided into three grades, namely mild, moderate, and severe. These three grades are further divided into different subgrades. The symptoms of UC can be divided into three grades, namely mild, moderate, and severe. The disease course can be divided into three grades, namely acute, subacute, and chronic. The disease stage can be divided into three grades, namely early, moderate, and late. The severity can be divided into three grades, namely mild, moderate, and severe. The sample size can be divided into three grades, namely small, medium, and large. The intervention measures can be divided into three grades, namely pharmacotherapy, nonpharmacotherapy, and a combination of the two. The drug dosage forms can be divided into three grades, namely decoctions, troches, powders, capsules, granules, pills, suppositories, ointments, injections, gels, oral liquids, and substitute tea. The intervention courses can be divided into three grades, namely short-term, medium-term, and long-term.
severe.\cite{13} The prevalence of UC in China is approximately 11.6 per 100,000 people.\cite{15} In recent years, the incidence of UC has been increasing. The long course of the disease and its high recurrence greatly affect the patient’s quality of life.\cite{4,5}

According to clinical manifestations, chronic diarrhea, hemostasis, mucus, and stomachaches associated with UC can be treated using Traditional Chinese Medicine (TCM).\cite{9} TCM can improve the clinical symptoms of UC, thus improving the quality of life of patients, enhancing confidence, and creating conditions for follow-up treatment.\cite{7}

Recently, several single-arm trials about TCM have shown good curative effects in the treatment of UC.\cite{8-12} Those cited reports have shown the same conclusion that TCM methods have curative effectiveness in result of curative effectiveness at TCM syndrome. In recent years, the number of randomized clinical trials (RCTs) of TCM has increased; therefore, it is very important to summarize the basic characteristics, quality, and types of intervention measures of these articles. A scoping review systematically maps a broad and diverse body of research evidence.\cite{13} We conducted this scoping review to systematically identify and describe RCTs in TCM for the treatment of UC to generate high-quality evidence-based information for clinicians and researchers.

**Materials and Methods**

**Literature search**

We searched the China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Database, Chinese CBM Database, the Cochrane Library, and PubMed from inception to January 2020. Search terms included “ulcerative colitis,” “UC,” “traditional Chinese medicine,” “traditional medicine, Chinese,” “Zhong Yi Xue,” “Chinese traditional medicine,” “Chinese medicine, traditional,” “cupping,” “scraping therapy,” “guasha,” “tuina,” “moxibustion,” and “acupuncture.”

We used Note Express software (Note Express. 3.2.0.6941. April 2016. Beijing Aegean Software Co., Ltd. Beijing, China.) to filter the titles and abstracts of the included articles. After filtering the abstract, we downloaded and filtered the full text of the article.

Microsoft Excel 2010 was used to extract the following data from the included studies: (1) basic information of the included studies, such as research ID, article title, publication language, journal, year of publication, and fund information; (2) patient information, including gender, age, disease course, disease stage, severity, sample size; and (3) information on intervention measures, types of intervention measures, drug dosage forms, and treatment courses. Only RCTs of Chinese medicines for treating UC were included.

The population, intervention, control, and outcomes strategy was used to guide researchers on the studies to be included to answer the research question. The study population comprised enrolled subjects from RCTs of TCMs for treating UC who were above 18 years of age irrespective of sex, course, and severity of illness.

The review focused on studies in which treatments were adopted based on the guidance of TCM theory or TCM treatment combined with western medicine. Those combinations are described as several TCM decoctions through oral or enema with one common medicine like mesalazine which developed and recommend by western countries. These treatments consisted of drug therapy, nondrug therapy, and a combination of drug and nondrug therapy. The included studies were compared to studies in which similar conventional western medicines for treating UC, their dosages, and course of treatment were reported. The outcome measures in the included studies were whether the patients were cured of their UC conditions or not after TCM therapy. The current scoping review was conducted and reported according to the PRISMA extension for scoping reviews.\cite{14}

We used the Cochrane Risk of Bias Assessment Tool to assess the risk of bias which was categorized as low, high, or unclear.\cite{15} The risk of bias assessment included random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other biases.

**Results**

**Description of the literature**

A total of 27,854 relevant studies were retrieved and 2225 RCTs were finally included after screening. The screening process is shown in Figure 1.

**Basic information of included trials**

In recent years, RCTs of TCM for UC have increased; the publication trend is shown in Figure 2. These studies covered several provinces in China. More than 100 related studies were carried out in Henan (257, 11.55%), Jiangsu (188, 8.45%), Shandong (167, 7.51%), Guangdong (165, 7.42%), Hebei (151, 6.79%), Hunan (117, 5.26%), and Hubei (111, 4.99%) provinces [Figure 3]. A total of 647 (29.71%) of the studies were conducted in less than a month. The basic information of the included studies is shown in Table 1. In addition, 2224 (99.96%) studies were published in Chinese, and 1665 (74.83%) of these studies did not report the severity of the disease.

Of the included studies, 2028 (91.15%) used drug therapy, 57 (2.56%) used nondrug therapy, and 140 (6.29%) used a combination of drug therapy and nondrug therapy.

According to Table 2, most of included RCTs made comparisons of TCM drugs versus western medicine straightly 1359 (61.08%). And the second largest comparisons form are TCM drug + western medicine versus western medicine 709 (31.87%).

The administration modes of the intervention groups are shown in Table 3. Drug therapy involved 12 types of TCM dosage forms, which were decoctions, troches, powders, capsules, granules, pills, suppositories, ointments, injections, gels,
oral liquids, and substitute teas according to the frequency of use [Figure 4]. Nondrug intervention measures involved 10 types of treatment measures, which were acupuncture, moxibustion, hemospasia, auricular point, acupoint catgut embedding, acupoint injection, scraping, tuina, acupoint application, and five-tone therapy according to the frequency of use [Figure 5].

Those included studies reported their results mainly in 12 forms of outcomes, which were clinical effective rate, therapeutic effect of TCM syndromes, score of TCM symptoms, therapeutic effect of enteroscope, Baron grade, factors of inflammation, blood routine, index of immunology, index of serum, disappearance time of the main symptom, adhesin, and flora levels.

Risk of bias in included trials
Most of the included studies did not describe random sequence generation and allocation concealment in detail or without description, and thus the risk of bias was “unclear.” There was almost no description of blinding of participants and personnel and blinding of outcome assessment [Figure 6]. A total of 1093 (49.12%) studies had only one author [Figure 7] and 414 (18.61%) studies were reported on less than one page.

Discussion
The incidence and prevalence of UC have increased gradually. TCM plays an important role in the treatment of UC and has attracted the attention of researchers in recent years. This review showed that more research on UC has been conducted in southern China than in northern China. This may be related to the higher incidence of UC in the former region. As UC is a chronic disease, its treatment must be observed to determine its long-term effectiveness. A course of treatment that lasts <28 days may affect outcomes.
and therefore, contribute to bias in the study results. Some studies did not report clear diagnostic criteria or the severity of UC. The internal validity of RCTs is affected if the subjects included are not strictly defined. Only one study was published in English, whereas others were published in Chinese, which is not conducive for international scholars to understand the effectiveness of TCM in treating UC.

The descriptions of random sequence generation and allocation concealment for the included RCTs are insufficient but are key links in the implementation of RCTs. Studies that did not
Table 3: Intervention approaches in the intervention groups

| Administration in the intervention group | RCTs, n (%) |
|----------------------------------------|-------------|
| Oral administration                      | 828 (37.21%)|
| Clysis                                  | 581 (26.11%)|
| Oral administration and clysis           | 688 (30.92%)|
| Acupoint application                     | 13 (0.58)  |
| Venous transfusion                       | 7 (0.31)   |
| Anal plug                                | 10 (0.45)  |
| Hot compress                             | 1 (0.05)   |
| Iontophoresis                            | 1 (0.05)   |
| Aerosol inhalation                       | 1 (0.05)   |
| Use of two or more administration methods| 45 (2.02)  |

RCTs: Randomized clinical trials

conclusIons

The methodological quality of most of the studies included in this review was low. Trials with rigorous methodology and improved quality of reporting are necessary to ensure that high-quality evidence exists to support clinical decision-making in UC. We, therefore, recommend that strategies to improve the quality of RCTs of TCM are identified and implemented to strengthen the evidence supporting the curative properties of traditional medicines for treating UC.

Study limitations

In this review, although we systematically searched multiple databases, there may still be omissions. In addition, the selection and extraction of data may lead to some bias. Among the RCTs included in this study, oral, clysis, and oral combined clysis were the most frequent modes of administration. The use of decoctions was highest in drug-based treatment modalities, whereas the use of acupuncture was the most common modality as a nondrug treatment approach. The results generated in the current study are based on published clinical research literature only; as such, the frequency of use of various treatments in practice may differ. Therefore, it is necessary to conduct investigations in a clinical setting to fully understand the use of various TCM treatment measures in clinical practice.

Future research

Future research should consider the following topics: (1) how to optimally obtain research data, utilize the data, and design research studies; (2) how to identify efficacious drugs with high safety profiles to further carry out high-quality original research, providing a foundation for condensing and developing the essence of TCM; 3. The appropriate endeavor should be spent in formulating the standard of RCTs about TCM methods’ publication in the future.

Acknowledgments

The authors would like to thank Yuan-Xi Li, a postgraduate student at the College of Statistics and Data Science, Faculty of Science, Beijing University of Technology, for help with research design.

Financial support and sponsorship

This study was financially supported by The National Natural Science Foundation of China (81904052) and The 13th Five-Year Plan for National Key R&D Program of China (2018YFC1705401).

Conflicts of interest

Prof. Jian-Ping Liu is an associate editors-in-chief of World Journal of Traditional Chinese Medicine. The article was subject to the journal's standard procedures, with peer review handled independently of this editorial board member and their research groups.

REFERENCES

1. Chen ZS. Guidelines for the diagnosis and treatment of ulcerative colitis. Mod Distance Educ Chin Tradit Med 2011;9:126-8.
2. Wu KC, Liang J, Ran ZH, Qian JM, Yang H, Chen WH, et al. Consensus opinions on the diagnosis and treatment of inflammatory bowel disease (Beijing, 2018). Chin J Pract Int Med 2018;38:796-813.
3. Zhao J, Ng SC, Burisch J, Lei Y, Li J, Zou K, et al. Tu1282 first
Zheng, et al. A scoping review of RCTs of TCM treating ulcerative colitis

World J Tradit Chin Med | Volume 7 | Issue 3 | July-September 2021

prospective, population-based inflammatory bowel disease incidence study in China - the emergence of “western” disease. Gastroenterology 2012;142, S–792.

4. Wang Y, Ouyang Q. APDW 2004 Chinese IBD working group. Ulcerative colitis in China: Retrospective analysis of 3100 hospitalized patients. J Gastroenterol Hepatol 2007;22:1450-5.

5. Zhang X, Shi EJ, Zhao PL, He YQ. Analysis of factors affecting the quality of life of patients with ulcerative colitis. J Chengdu Univ Tradit Chin Med 2018;41:96-100.

6. Zhang SS, Shen H, Zheng K, Ye B. Consensus of TCM experts on diagnosis and treatment of ulcerative colitis (2017). Chin J Tradit Chin Med 2017;32:3585-9.

7. Han X, Li J. Key issues and advantages of TCM treatment from the perspective of writing “technical guidelines for clinical research of new Chinese medicine for ulcerative colitis”. Chin J Integr Chin West Med Dig 2019;27:541-5.

8. Zhibin W, Chen C, Yi G, Shi L, Sun ZM, Mao TY, et al. Clinical study of Qingchang Wenzhong on mild to moderate ulcerative colitis. Chin J Integr Tradit West Med 2018;33:312-6.

9. Zhibin W, Chen C, Yi G, Shi L, Sun ZM, Mao TY, et al. Clinical study of Qingchang Wenzhong on mild to moderate ulcerative colitis. Chin J Integr Tradit West Med 2018;33:312-6.

10. Banner ZT, Bo Y, Xinyuan T, Gong Q, Chen BY, Wu ZJ. Compound radix sophorae flavescentis colonic capsule in the treatment of ulcerative colitis of damp-heat intrinsic type: A multicenter, randomized, double-blind, controlled study. Chinese Journal of Integrated Traditional and Western Medicine 2011;31:172-6.

11. Liu H. Compound radix sophorae flavescentis colonic capsule in the treatment of 24 cases of ulcerative colitis. Chin J Integr Tradit West Med Dig Dis 2012;20:86-8.

12. Grimshaw J. A Guide to Knowledge Synthesis. Canadian Institutes of Health Research, https://cihr-irsc.gc.ca/e/41382.html. 2010.

13. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 2018;169:467-73.

14. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

15. APDW 2004 Chinese IBD Working Group. Retrospective analysis of 515 cases of Crohn’s disease hospitalization in China: Nationwide study from 1990 to 2003. J Gastroenterol Hepatol 2006;21:1009-15.

16. Wang CJ, Hao WW, Tang DX, Li YF, Wen YD, Wang FY, et al. TCN diagnosis and treatment guidelines for common diseases of digestive system (primary doctor edition). Chin J Tradit Chin Med 2019;34:4721-6.

17. Zheng WW, Pan KL, Liu SX, Xu LH. Discussion on TCM diagnosis and treatment of ulcerative colitis. Chin Med Inform 2019;36:125-8.

18. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.

19. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials 2005;26:480-7.

20. Egger M, Smith GD, Sterne JA. Uses and abuses of meta-analysis. Clin Med (Lond) 2001;1:478-84.